key: cord-0738607-0gk24ch7
authors: Zhao, Fangzhu; Yuan, Meng; Keating, Celina; Shaabani, Namir; Limbo, Oliver; Joyce, Collin; Woehl, Jordan; Barman, Shawn; Burns, Alison; Zhu, Xueyong; Ricciardi, Michael; Peng, Linghang; Smith, Jessica; Huang, Deli; Briney, Bryan; Sok, Devin; Nemazee, David; Teijaro, John R.; Wilson, Ian A.; Burton, Dennis R.; Jardine, Joseph G.
title: Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution
date: 2021-05-30
journal: bioRxiv
DOI: 10.1101/2021.05.29.443900
sha: d7d7f9dea228550d6258fc9103e6837847e9bf39
doc_id: 738607
cord_uid: 0gk24ch7

The emergence of SARS-CoV-2 underscores the need for strategies to rapidly develop neutralizing monoclonal antibodies that can function as prophylactic and therapeutic agents and to help guide vaccine design. Here, we demonstrate that engineering approaches can be used to refocus an existing neutralizing antibody to a related but resistant virus. Using a rapid affinity maturation strategy, we engineered CR3022, a SARS-CoV-1 neutralizing antibody, to bind SARS-CoV-2 receptor binding domain with >1000-fold improved affinity. The engineered CR3022 neutralized SARS-CoV-2 and provided prophylactic protection from viral challenge in a small animal model of SARS-CoV-2 infection. Deep sequencing throughout the engineering process paired with crystallographic analysis of an enhanced antibody elucidated the molecular mechanisms by which engineered CR3022 can accommodate sequence differences in the epitope between SARS-CoV-1 and SARS-CoV-2. The workflow described provides a blueprint for rapid broadening of neutralization of an antibody from one virus to closely related but resistant viruses.

6 All variants showed enhanced neutralization of SARS-CoV-1, with the most potent neutralizing at 160 0.5 µg/mL compared to the parental CR3022 that neutralizes at 10.9 µg/mL (Figures 2D, 2E) . In 161 our assay, CR3022 failed to neutralize SARS-CoV-2 at a maximum antibody concentration of 100 162 µg/mL (Figures 2D, 2F) . In contrast, all eCR3022 antibodies were able to neutralize pseudotyped 163 SARS-CoV-2 with a median IC50 of 1.6 µg/mL, with the most potent neutralizing SARS-CoV-2 164 exhibiting an IC50 of 0.3 µg/mL ( Figures 2D, 2F) . We further tested the neutralization activity of 165 eCR3022.7, eCR3022.10 and eCR3022.20 against the emerging variants of concern B.1.1.7 (with 166 N501Y mutation on RBD) and B.1.351 (with K417N, E484K, N501Y mutations on RBD) variants 167 (Tegally et al.) , where the mutations are located in the receptor binding site on the RBD and are 168 outside the CR3022 epitope. As expected, eCR3022 antibodies neutralized both viral variants 169 with similar IC50 to the wildtype virus SARS-CoV-2 ( Figure S6 ). Lastly, the eCR3022 variants were 170 able to neutralize authentic SARS-CoV-2 virus while CR3022 failed to neutralize, confirming the 171 neutralization against authentic virus ( Figure S7 ). 172 Table S3 ). Two copies of the eCR3022.20-RBD-CC12.3 complex were 178 found in the crystal asymmetric unit. eCR3022.20 binds SARS-CoV-2 RBD via the same epitope 179 as CR3022 through a nearly identical angle of approach (Yuan et al., 2020a) ( Figure 3A ). 180 Furthermore, the RBD conformation bound by both antibodies are almost identical, except for two 181 regions of the RBD (residues 365-370 and 384-390) that are displaced in eCR3022.20 compared 182 to CR3022 ( Figure 3B ). However, residues in both of these regions (RBD-Y369, F377, and P384) 183 form a hydrophobic pocket that interact with CDRH1 of these antibodies ( Figures 3C-3F ). VH T31 184 in CDRH1 of CR3022 ( Figure 3C ) is substituted by a bulky hydrophobic, aromatic residue W31, 185 which stacks with RBD residues Y369, F377, and P384 and strengthens the interaction with this 186 hydrophobic pocket in the RBD ( Figures 3D, 3E ). The T31W substitution induces a 2.4-Å shift in 187 the RBD around residues 365-370, as well as a 1.4-Å shift of residues 384-390 ( Figure 3F ). 188

Previously, we showed that residue 384 is an important epitope residue for CR3022 binding, 189

where a P384A mutation conferred an approximate 100-fold affinity improvement for CR3022 (Wu 190 et al., 2020a) . Here, we show that a substitute paratope residue targeting this area of the epitope 7 is able to contribute to an improvement in antibody binding and further highlights the importance 192 of P384 as a key epitope residue for CR3022. 193 In addition to CDRH1, CDRH2 of both CR3022 and eCR3022.20 interact with SARS- 2 RBD (Figures 3G, 3H) . For both antibodies, VH Y52 forms a hydrogen bond with the backbone 195 amide of RBD-F377. VH D54 and E56 clamp onto RBD-K378 with two salt bridges (Figures 3G, 196 3H) . CDRH2 in both antibodies form a type-IV β (Lewis et al., 1973) at the CDR tip, where VH S55 197 (i+3) in CR3022 is substituted by a glycine in most sorted antibody variants during the process of 198 affinity maturation ( Figure 1B ; Figure S9 ). Glycine is frequently found in β turns due to the lack of 199 a side chain that allows higher conformational flexibility. Indeed, glycine is the most frequent 200 residue at the i+3 position of a type-IV β turn, suggesting that it is energetically favored at this 201 position as it can also more readily adopt a positive phi value as found here compared to S55 202 (Guruprasad and Rajkumar, 2000) . For the light-chain residues, VL Y31 and S99 are mutated to 203 W31 and K99 in eCR3022.20 (Figures 3I, 3J) . While VL W31 retains hydrophobic interactions with 204 RBD-Y380, P412, and F429, VL K99 is able to form a cation-π interaction with W31, which 205 stabilizes the interaction between CDRs L1 and L3 and may reduce the entropy of its interaction 206 with the RBD. 207

Protection by eCR3022 against SARS-CoV-2 challenge in a small animal model 208 Upon developing a CR3022 variant capable of neutralizing SARS-CoV-2, we sought to 209 evaluate whether this engineered antibody could provide prophylactic protection against viral 210 challenge in the Syrian hamster model. Based on the neutralization and biophysical data, 211 eCR3022.7 was selected as our initial candidate antibody to evaluate. Groups of six hamsters 212 received an intraperitoneal infusion 10 mg, 2 mg, 0.5 mg, or 0.125 mg of eCR3022.7 per animal 213 to evaluate dose-dependent protection. Another group received 10 mg of the parental CR3022 214 antibody and a control group received 10 mg of an anti-dengue isotype matched antibody. Three 215 days post infusion, sera were collected from each animal to determine antibody titer at the time 216 of viral challenge. Animals were then challenged with 1 x 10 5 plaque forming units (PFU) of SARS-217

CoV-2 (USA-WA1/2020) by intranasal administration. The hamsters were weighed daily as a 218 measure of disease due to infection and sera were collected from all animals at the conclusion of 219 the experiment on day 7. Hamsters have been shown to clear SARS-CoV-2 infection after 7 days 220 (Sia et al., 2020) , so a replicate of the original experiment was performed with six additional 221 animals in which lung tissue was collected on day 4 to accurately measure replicative viral load 222 amongst the groups ( Figure 4A ). 223 8 The groups receiving the highest doses of eCR3022.7 of 10 mg or 2 mg were largely 224 protected from viral challenge, exhibiting either no weight loss or 3% weight loss, respectively, at 225 the end of the 7-day experiment ( Figure 4B ; Figure S10 ). In contrast, the group that received 10 226 mg of the original CR3022 antibody lost 11% of body weight, comparable to the control group that 227 received 10 mg of Den3. The groups that received 0.5 mg or 0.125 mg eCR3022.7 on average 228 lost slightly less weight than the control group but the difference was not significant (Table S4) . 229

Lung viral titers were assessed from the second group of animals by plaque assay ( Figure 4C ). 230

Equivalent viral loads were measured between the control Den3 and original CR3022 groups with 231 average of 4.0 x 10 6 PFU/mL and 6.8 x 10 5 PFU/mL, respectively (Table S4 ). In contrast, the 232 groups that received 10 mg or 2 mg doses of eCR3022.7 had 7.0 x 10 4 PFU/mL and 8.7 x 10 4 233 PFU/mL, respectively, more than 2 logs lower than the Den3 control. The reduced SARS-CoV-2 234 viral lung titers and maintenance of body weight following challenge in the animals receiving either 235 10 mg or 2 mg doses prophylactically of eCR3022.7 demonstrate that the in vitro neutralization 236 potency translates to in vivo protection. Serum antibody concentrations were measured both at 237 the time of challenge and the end of the study. The 10 mg eCR0322.7 and 10 mg CR3022 groups 238 had an equivalent amount of antibody present at the time of injection as well as equivalent decay 239 by day 7, confirming that the observed protection differences are not attributable to different 240 pharmacokinetic properties of the two antibodies ( Figure 4D , Figure S10B ). 241

Antibody refocusing serves as a novel approach to generate neutralizing antibodies 243 against novel viruses or viral variants, provided that a neutralizing antibody against a closely 244 related virus is available. In this case study, we successfully re-engineered a SARS-CoV-1 nAb, 245 CR3022, so that it now potently neutralized both SARS-CoV-1 and SARS-CoV-2. eCR3022 246 variants with >1000-fold enhanced affinity for SARS-CoV-2 RBD were generated while 247 maintaining their biochemically favorable developability profile. The enhanced affinity conferred 248 the ability to potently neutralize SARS-CoV-2 and protect from viral challenge in a small animal 249 model. In fact, the eCR3022 variants now neutralize SARS-CoV-2 more potently than the parental 250 CR3022 neutralizes SARS-CoV-1. These findings are consistent with previous studies showing 251 a relationship between antibody/antigen binding affinity for S protein and neutralization potency. 252

However, this is the first instance that we are aware of where an antibody has been specifically 253 retargeted or optimized to a novel related virus. Although this refocusing strategy likely will not be 254 effective when the antibody epitope is substantially different between viruses (Figure S11), the 255 9 potential pool of starting antibodies continues to expand as more neutralizing antibodies are 256 discovered against different viruses. We also note that the use of on-chip DNA synthesis to 257 rationally produce the CDR libraries used in our SAMPLER optimization allowed us to efficiently 258 cover a large portion of the theoretical search space within the antibody paratope, effectively 259 achieving these affinity gains in a two-step process. Given that the affinity engineering described 260 can be done in less than one month and does not require access to PBMC samples from 261 immunized or infected donors or structural information on the antibody/antigen interaction, the 262 approach could be used in conjunction with conventional antibody discovery as a rapid response 263 to future outbreaks of pandemic concern. 264 265

Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., et al. 

e Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement. Table S3 . X-ray data collection and refinement statistics. Related to Figure 3 . 496 Table S4 

In brief, S or RBD 757 expression plasmids were cotransfected with 40K PEI (1 mg/mL) at a ratio of 1:3. After incubation 758 for 30 min at RT, transfection mixture was added to Freestyle 293F cells at a density of 759 approximately 1 million cells/mL. After 5 days

After three columns of washing with 25 mM Imidazole (pH 7.4), proteins were 762 eluted with an elution buffer (250 mM Imidazole, pH 7.4) at slow gravity speed (~4 sec/drop)

Eluted proteins were buffer exchanged and concentrated with PBS using Amicon tubes 764 (Millipore). The proteins were further purified by size exclusion chromatography (SEC) using

Superdex 200 (GE Healthcare). The selected fractions were pooled and concentrated again for

Monoclonal antibody was transiently expressed in the Expi293 system (ThermoFisher, A14635)

In brief, antibody HC and LC plasmids were co-transfected at a ratio of 1:2.5 with transfection 771

After 24 h of transfection, 300 mM of sterile sodium 772 valproic acid solution (Sigma-Aldrich, P4543) and 45% D-(+)-glucose solution

After 4-5 days of transfection

Healthcare 17-5280-04)

Pseudovirus neutralization assay

Pseudovirus was generated as described previously 2

We thank Laurence Cagnon at The Scripps Research Institute for coordinating with BSL-3 383 experiments. We thank Scripps Genomic Core facility for the help of deep sequencing. We thank

The libraries were displayed on the surface of yeast as molecular Fab using the pYDSI vector, a 605 yeast display vector containing the bidirectional Gal1-10 promoter that was based on the design 606 of a previously described vector (Wang et al., 2018) , omitting the leucine-zipper dimerization 607 domains. The heavy chain contains a C-terminal V5 epitope tag and the light chain contains a C-608 terminal C-myc epitope tag to assess the amount of Fab displayed on the surface of the yeast. 609The HC library was generated by cloning the HC CDR1/2/3 library into a vector already containing 610 the invariant CR3022 light chain by homologous recombination, and the LC library was generated 611 by doing the inverse. The HC/LC library was generated by amplifying the HC and LC sequences 612 with primers overlapping in the Gal1-10 promoter. The recovered Gal-HC and Gal-LC fragments 613 were ligated via Gibson assembly and amplified. The resulting LC-Gal1-10-HC product was 614 cloned into empty pYDSI by homologous recombination. 615 616

Yeast transformation was performed as described previously. In brief, the colony of 618Saccharomyces cerevisiae YVH10 cells (ATCC, MYA4940) was inoculated in 2mL YPD medium 619 (Dissolve 20 g dextrose, 20 g peptone and 10 g yeast extract in deionized H2O to a volume of 1 620 liter and sterilize by filtration) and shaken overnight at 30°C. The overnight culture was expanded 621 in 50 mL YPD medium and shaken at 30°C until the absorbance was around 1.5 at 600 nm. Yeast 622 cells were spun down and resuspended with 25 mL of 100 mM lithium acetate. 250 µL of 1 M 623 37 DTT was added to the cells and mixed rapidly. After shaking at 30°C for 10 min, cells were spun 624 down and washed with 25 mL of pre-chilled deionized H2O. After centrifuge, the cell pellet was 625 suspended with pre-chilled deionized H2O to a final volume of 500 µL. After this step, yeast cells 626 were electrocompetent and ready for transformation. After yeast transformation, yeast cells were expanded and split once for better display efficiency. 644Before staining, cells were induced overnight at 30°C by SGCAA induction medium (dissolve 20 645 g galactose, 1 g glucose, 6.7 g yeast nitrogen base without amino acid, 5 g bacto casamino acids, 646 5.4 g Na2HPO4, 8.56 g NaH2PO4!"2O, 8.56 mg uracil to 1 L deionized water, pH 6.5, and sterilize 647 by filtration). For each library, in the first round of selection, 5 x 10 7 of yeast cells were stained per 648 sample. In the second to final round of selection, 1 x 10 7 cells were stained. Yeast cells were 649 firstly spun down and washed with PBS/1% BSA, then incubated with biotinylated SARS-CoV-2 650 RBD or S or HEK cell membrane protein at several non-depleting concentrations respectively for 651 at least 30 min at 4°C. After washing, yeast cells were stained with FITC-conjugated chicken anti- Paired FASTQs were checked for sequence quality using the FastQC package (FastQC v0.11.9 ) . 718The forward and reverse reads were merged using BBMerge (version 38.87) from the BBTools 719 suite using standard parameters (Bushnell et al., 2017) . Merged reads with full sequence identity 720 were clustered using VSEARCH (v2.15.1) (Rognes et al., 2016) . Clustering was done using the 721 "cluster_fast" method and fasta files were written including cluster abundance in the fasta header. 722 40 A custom python (Python 3.7) script was written to parse the vsearch output, translate the DNA 723 sequences to amino acid sequences and count the CDR1, CDR2, and CDR3 positions.